MISSION TO RAISE AWARENESS OF SARCOMA AND CLINICAL TRIAL FUNDING Research lagging for sarcoma, despite accounting for one third of adolescent cancer deaths
With
Associate Professor Jeremy Lewin, Medical Oncologist,
Peter MacCallum Cancer Centre & Medical Director,
Victorian Adolescent and Young Adult Cancer Service &
Research & Education Lead – Sarcoma, VCCC Alliance
Dr Vivek Bhadri,
Paediatric and Adolescent Medical Oncologist
Chris O’Brien Lifehouse & Westmead Public Hospital &
Board Director
Australia and New Zealand Sarcoma Association (ANZSA)
AUSTRALIAN HEALTH JOURNAL SEGMENT
Filmed in Sydney & Melbourne | September 2025
Sarcoma, a rare and aggressive cancer, remains the deadliest cancer for children and young adults, accounting for nearly one third (30%) of cancer-related deaths among those aged 15–24 and one tenth (10%) of those aged 0–14. Further, still severely under-diagnosed, sarcoma only accounts for one sixth (15%) of all cancer diagnoses in the 15 – 24 age group, and less than a tenth (8%) among children under 10.
Despite this, public awareness and research funding for sarcoma funding remain critically low, with sarcoma receiving just $4.6m in funding for research in 2018-2020 – compared to the tens of millions other cancers receive. Sarcoma gets only a tiny fraction of funding for research that more common cancers receive, despite having the same costs to conduct studies.
The lack of funding reflects long-term survival rates for sarcoma which remain concerningly low, at just a 50% 10-year survival rate, while five-year survival rates for common cancers such as prostate and breast cancer have increased to over 90% in the past four decades (96% and 92% respectively).
Accounting for just 1% of all adult cancer diagnoses, sarcomas are rare and complex cancers that form in bone, cartilage or soft tissue8. There are over 100 different subtypes of sarcoma, which each require their own diagnostic and treatment pathways, which is why continued research is essential to improving patient outcomes.
Research indicates sarcomas are misdiagnosed in nearly one third (30%) of cases, emphasising the importance of ongoing research to support diagnostic developments, alongside improvements in patient treatment and management pathways.
Source: Australian and New Zealand Sarcoma Association (ANZSA) media release 1 July 2025
-
Bridging the orthodontic knowledge gap
In recent years, the orthodontic sector has been growing rapidly due to success in B2C marketing and companies like Invisalign reaching the consumer, but there has also been a lack of knowledge sharing among general dental practitioners and specialists.
General dentists require mentorship and guidance from orthodontists to feel confident in providing orthodontic treatment to their patients, ultimately improving the quality of care in the community.
-
Improved treatment in advanced-stage Hodgkin lymphoma
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.
-
Reducing patient accessibility barriers in the clinical setting
Hannah McPierzie is a globally respected presenter, disability advocate, and educator who offers a unique perspective on disability and communication. She lives with Neurofibromatosis Type 2, a rare degenerative condition, and has two auditory brainstem implants. After 15 years teaching in the disability sector, Hannah acquired disability herself in 2020, when life-saving surgery left her deafblind.
